Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection

PHASE3RecruitingINTERVENTIONAL
Enrollment

768

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

January 16, 2026

Study Completion Date

January 30, 2026

Conditions
Gastric Cancer
Interventions
DRUG

Capecitabine monotherapy

Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.

Trial Locations (1)

230022

RECRUITING

The First Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

The First Affiliated Hospital of Anhui Medical University

OTHER